Price to Sales (P/S)
since 2005
Paying user area
Try for free
Cytokinetics Inc. pages available for free this week:
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common Stock Valuation Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cytokinetics Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Cytokinetics Inc., P/S, long-term trends, calculation
| P/S | = | Share price1, 2, 3 | ÷ | Sales per share1 | Sales per share1 | = | Revenues1 (in thousands) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | = | ÷ | = | ÷ | |||||||
| Feb 25, 2022 | = | ÷ | = | ÷ | |||||||
| Feb 26, 2021 | = | ÷ | = | ÷ | |||||||
| Mar 4, 2020 | = | ÷ | = | ÷ | |||||||
| Mar 7, 2019 | = | ÷ | = | ÷ | |||||||
| Mar 5, 2018 | = | ÷ | = | ÷ | |||||||
| Mar 6, 2017 | = | ÷ | = | ÷ | |||||||
| Mar 3, 2016 | = | ÷ | = | ÷ | |||||||
| Mar 6, 2015 | = | ÷ | = | ÷ | |||||||
| Mar 7, 2014 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2013 | = | ÷ | = | ÷ | |||||||
| Mar 13, 2012 | = | ÷ | = | ÷ | |||||||
| Mar 11, 2011 | = | ÷ | = | ÷ | |||||||
| Mar 11, 2010 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2009 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2008 | = | ÷ | = | ÷ | |||||||
| Mar 12, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 10, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Cytokinetics Inc. Annual Report.
- Share Price
- The share price exhibits substantial volatility over the analyzed period. Initially, it was relatively high at $42.90 in 2006 and experienced a significant decline to $12 by 2009. This was followed by fluctuations with a low of $6.30 in 2013, then a modest recovery and further volatility until around 2019 with values mostly under $15. From 2020 onward, the share price shows a marked upward trend, nearly tripling from $14.86 in 2020 to $43.11 in 2023, returning to levels comparable to the earliest observations.
- Sales per Share
- Sales per share present a non-linear pattern with frequent fluctuations and no sustained upward or downward trend. The values oscillate between lows of $0.23 to $0.31 over multiple years and notable peaks such as $7.83 in 2010 and $2.55 in 2017. This suggests inconsistent sales generation relative to share count, with no clear improvement over the long term. More recent years (2021 to 2023) show a mild increase from $0.79 to $0.99, indicating some recovery or growth in sales per share.
- Price-to-Sales (P/S) Ratio
- The P/S ratio is highly variable, reflecting both the fluctuations in share price and sales per share. It started very elevated at 28.53 in 2006 and peaked dramatically at 112.43 in 2007, indicating a very high valuation relative to sales. A general decreasing trend is observed between 2007 and 2011, bottoming out near 2.57 in 2010. Subsequently, the ratio displays cyclical spikes and drops, with another significant peak at 42.19 in 2022 and a slight increase thereafter to 43.37 in 2023. These trends suggest that the market valuation relative to sales has endured periods of both undervaluation and overvaluation, potentially driven by market sentiment or expectations beyond the actual sales performance.
- Overall Insights
- The company's market valuation as reflected by share price and P/S ratio has experienced considerable volatility without consistent growth tied closely to sales per share. The recent upward momentum in share price combined with rising P/S ratios might reflect market optimism or expectations of future improvement rather than improvements in current sales metrics. The fluctuating sales per share and the decoupling from share price indicate a potential gap between operational performance and market valuation throughout much of the period under review.
Comparison to Competitors
Cytokinetics Inc., P/S, long-term trends, comparison to competitors
| Cytokinetics Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 1, 2023 | |||||||||||||
| Feb 25, 2022 | |||||||||||||
| Feb 26, 2021 | |||||||||||||
| Mar 4, 2020 | |||||||||||||
| Mar 7, 2019 | |||||||||||||
| Mar 5, 2018 | |||||||||||||
| Mar 6, 2017 | |||||||||||||
| Mar 3, 2016 | |||||||||||||
| Mar 6, 2015 | |||||||||||||
| Mar 7, 2014 | |||||||||||||
| Mar 15, 2013 | |||||||||||||
| Mar 13, 2012 | |||||||||||||
| Mar 11, 2011 | |||||||||||||
| Mar 11, 2010 | |||||||||||||
| Mar 12, 2009 | |||||||||||||
| Mar 12, 2008 | |||||||||||||
| Mar 12, 2007 | |||||||||||||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Cytokinetics Inc., P/S, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
| Cytokinetics Inc. | Pharmaceuticals, Biotechnology & Life Sciences | |
|---|---|---|
| Mar 1, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Mar 4, 2020 | ||
| Mar 7, 2019 | ||
| Mar 5, 2018 | ||
| Mar 6, 2017 | ||
| Mar 3, 2016 | ||
| Mar 6, 2015 | ||
| Mar 7, 2014 | ||
| Mar 15, 2013 | ||
| Mar 13, 2012 | ||
| Mar 11, 2011 | ||
| Mar 11, 2010 | ||
| Mar 12, 2009 | ||
| Mar 12, 2008 | ||
| Mar 12, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Cytokinetics Inc., P/S, long-term trends, comparison to industry (health care)
| Cytokinetics Inc. | Health Care | |
|---|---|---|
| Mar 1, 2023 | ||
| Feb 25, 2022 | ||
| Feb 26, 2021 | ||
| Mar 4, 2020 | ||
| Mar 7, 2019 | ||
| Mar 5, 2018 | ||
| Mar 6, 2017 | ||
| Mar 3, 2016 | ||
| Mar 6, 2015 | ||
| Mar 7, 2014 | ||
| Mar 15, 2013 | ||
| Mar 13, 2012 | ||
| Mar 11, 2011 | ||
| Mar 11, 2010 | ||
| Mar 12, 2009 | ||
| Mar 12, 2008 | ||
| Mar 12, 2007 | ||
| Mar 10, 2006 |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).